Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Quality of Life Research
Published in: Quality of Life Research 4/2022

Open Access 01-04-2022 | Irritable Bowel Syndrome

The estimation of a preference-based single index for the IBS-QoL by mapping to the EQ-5D-5L in patients with irritable bowel syndrome

Authors: Rosel Sturkenboom, Daniel Keszthelyi, Lloyd Brandts, Zsa Zsa R. M. Weerts, Johanna T. W. Snijkers, Ad A. M. Masclee, Brigitte A. B. Essers

Published in: Quality of Life Research | Issue 4/2022

Login to get access

Abstract

Purpose

The Irritable Bowel Syndrome Quality of Life (IBS-QoL) questionnaire is a commonly used and validated IBS-specific QoL instrument. However, this questionnaire is in contrast to the EQ-5D-5L, not preference-based and as such does not allow calculation of QALYs. The objective of this study was to describe the convergent- and known-group validity of both questionnaires and to develop a mapping algorithm from EQ-5D-5L which enable IBS-QoL scores to be transformed into utility scores for use in economic evaluations.

Methods

We used data from two multicenter randomized clinical trials, which represented the estimation and external validation dataset. The convergent validity was investigated by examining correlations between the EQ-5D-5L and IBS-QoL and the known-group validity by calculating effect sizes. Ordinary least squares (OLS), censored least absolute deviations (CLAD), and mixture models were used in this mapping approach.

Results

283 IBS patients were included (n = 189 vs. n = 84). Mean IBS-QoL score was 71.13 (SD 15.66) and mean EQ-5D-5L utility score was 0.73 (SD 0.19). The overall sensitivity of the IBS-QoL and EQ-5D-5L to discriminate between patient and disease characteristics was similar. CLAD model 4, containing the total IBS-QoL score and squared IBS-SSS (IBS severity scoring system), was chosen as the most appropriate model to transform IBS-QoL scores into EQ-5D-5L utility scores.

Conclusion

This study reports the development of an algorithm where the condition-specific questionnaire IBS-QoL can be used to calculate utility values for use in economic evaluations. Including a clinical measure, IBS-SSS, in the model improved the performance of the algorithm.
Appendix
Available only for authorised users
Literature
1.
Palsson, O. S., Whitehead, W., Törnblom, H., Sperber, A. D., & Simren, M. (2020). Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology, 158, 1262-1273.e3.PubMed
2.
Canavan, C., West, J., & Card, T. (2014). Review article: The economic impact of the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 40, 1023–1034.PubMed
3.
Spiegel, B., Harris, L., Lucak, S., Mayer, E., Naliboff, B., Bolus, R., et al. (2009). Developing valid and reliable health utilities in irritable bowel syndrome: Results from the IBS PROOF cohort. American Journal of Gastroenterology, 104, 1984–1991.
4.
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., et al. (2018). American college of gastroenterology monograph on management of irritable bowel syndrome. American Journal of Gastroenterology, 113, 1–18.
5.
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., et al. (2021). ACG clinical guideline: Management of irritable bowel syndrome. The American Journal of Gastroenterology, 116, 17–44.PubMed
6.
7.
8.
Bushnell, D. M., Martin, N. L., Ricci, J. F., & Bracco, A. (2006). Performance of the EQ-5D in patients with irritable bowel syndrome. Value in Health, 9, 90–97.PubMed
9.
EuroQol Group. (1990). EuroQol—a new facility for the measurement of health-related quality of life. Health Policy, 16, 199–208.
10.
Brooks, R., & de Charro, F. (1996). EuroQol: The current state of play. Health Policy, 37, 53–72.PubMed
11.
Bushnell, D. M., Reilly, M. C., Galani, C., Martin, M. L., Ricci, J. F., Patrick, D. L., et al. (2006). Validation of electronic data capture of the irritable bowel syndrome—Quality of life measure, the work productivity and activity impairment questionnaire for irritable bowel syndrome and the EuroQol. Value in Health, 9, 98–105.PubMed
12.
Paré, P., Gray, J., Lam, S., Balshaw, R., Khorasheh, S., Barbeau, M., et al. (2006). Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: Baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic study. Clinical Therapeutics, 28, 1726–1735.PubMed
13.
14.
Sánchez-Cuén, J. A., Irineo-Cabrales, A. B., Bernal-Magaña, G., & Peraza-Garay, F. D. J. (2017). Calidad de vida relacionada con la salud en adultos con síndrome de intestino irritable en un hospital de especialidades de méxico. Estudio transversal. Revista Espanola de Enfermedades Digestivas, 109, 265–272.PubMed
15.
Drossman, D. A., Patrick, D. L., Whitehead, W. E., Toner, B. B., Diamant, N. E., Hu, Y., et al. (2000). Further validation of the IBS-QOL: A disease-specific quality-of-life questionnaire. American Journal of Gastroenterology, 95, 999–1007.
16.
Wiebe, S., Guyatt, G., Weaver, B., Matijevic, S., & Sidwell, C. (2003). Comparative responsiveness of generic and specific quality-of-life instruments. Journal of Clinical Epidemiology, 56, 52–60.PubMed
17.
18.
19.
Patrick, D. L., & Deyo, R. A. (1989). Generic and disease-specific measures in assessing health status and quality of life. Medical Care, 27, S217–S232.PubMed
20.
Zamani, M., Alizadeh-Tabari, S., & Zamani, V. (2019). Systematic review with meta-analysis: The prevalence of anxiety and depression in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 50, 132–143.PubMed
21.
Lee, V., Guthrie, E., Robinson, A., Kennedy, A., Tomenson, B., Rogers, A., et al. (2008). Functional bowel disorders in primary care: Factors associated with health-related quality of life and doctor consultation. Journal of Psychosomatic Research, 64, 129–138.PubMed
22.
Weerts, Z. Z. R. M., Vork, L., Mujagic, Z., Keszthelyi, D., Hesselink, M. A. M., Kruimel, J., et al. (2019). Reduction in IBS symptom severity is not paralleled by improvement in quality of life in patients with irritable bowel syndrome. Neurogastroenterology and Motility, 31, 1–10.
23.
Thijssen, A. Y., Jonkers, D. M., Leue, C., van der Veek, P. P. J., Vidakovic-Vukic, M., van Rood, Y. R., et al. (2010). Dysfunctional cognitions, anxiety and depression in irritable bowel syndrome. Journal of Clinical Gastroenterology, 44, e236–e241.PubMed
24.
Ranaboldo, C. J., Chant, A. D. B., & Harwood, R. (1992). Reprocessing data to form QALYs [5]. British Medical Journal, 305, 424.PubMedPubMedCentral
25.
Earnshaw, J., & Lewis, G. (2008). NICE guide to the methods of technology appraisal: Pharmaceutical industry perspective. PharmacoEconomics, 26, 725–727.PubMed
26.
Chuang, L. H., & Whitehead, S. J. (2012). Mapping for economic evaluation. British Medical Bulletin, 101, 1–15.PubMed
27.
Wailoo, A. J., Hernandez-Alava, M., Manca, A., Mejia, A., Ray, J., Crawford, B., et al. (2017). Mapping to estimate health-state utility from non–preference-based outcome measures: An ISPOR good practices for outcomes research task force report. Value in Health, 20, 18–27.PubMed
28.
Weerts, Z. Z. R. M., Masclee, A. A. M., Witteman, B. J. M., Clemens, C. H. M., Winkens, B., Brouwers, J. R. B. J., et al. (2020). Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome. Gastroenterology, 158, 123–136.PubMed
29.
Schmulson, M. J., & Drossman, D. A. (2017). What is new in Rome IV. Journal of Neurogastroenterology and Motility, 23, 151–163.PubMedPubMedCentral
30.
31.
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20, 1727–1736.PubMedPubMedCentral
32.
Versteegh, M., Vermeulen, K. M., Evers, S. M. A. A., deWit, G. A., Prenger, R., & Stolk, E. A. (2016). Dutch tariff for the five-level version of EQ-5D. Value in Health, 19, 343–352.
33.
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998). Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Digestive Diseases and Sciences, 43, 400–411.PubMed
34.
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166, 1092–1097.PubMed
35.
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16, 606–613.PubMedPubMedCentral
36.
Löwe, B., Gräfe, K., Zipfel, S., Spitzer, R. L., Herrmann-Lingen, C., Witte, S., et al. (2003). Detecting panic disorder in medical and psychosomatic outpatients: Comparative validation of the Hospital Anxiety and Depression Scale, the Patient Health Questionnaire, a screening question, and physicians’ diagnosis. Journal of Psychosomatic Research, 55, 515–519.PubMed
37.
Francis, C. Y., Morris, J., & Whorwell, P. J. (1997). The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Alimentary Pharmacology and Therapeutics, 11, 395–402.PubMed
38.
Brazier, J., & Deverill, M. (1999). A checklist for judging preference-based measures of health related quality of life: Learning from psychometrics. Health Economics, 8, 41–51.PubMed
39.
Rosnow, R. L., & Rosenthal, R. (1996). Computing contrasts, effect sizes, and counternulls on other people’s published data: General procedures for research consumers. Psychological Methods, 1, 331–340.
40.
Hedges, L. V. (1981). Distribution theory for glass’s estimator of effect size and related estimators. Journal of Educational Statistics, 6, 107–128.
41.
Hedges, L. V., & Olkin, I. (1985). Statistical Methodology in Meta-Analysis. San Diego, CA: Academic Press.
42.
Brazier, J. E., Yang, Y., Tsuchiya, A., & Rowen, D. L. (2010). A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. European Journal of Health Economics, 11, 215–225.
43.
Hillside, N. J. (1988). Statistical Power Analysis for the Behavioral Sciences. Mahway: Lawrence Erlbaum Associates.
44.
Mukuria, C., Rowen, D., Harnan, S., Rawdin, A., Wong, R., Ara, R., et al. (2019). An updated systematic review of studies mapping (or cross-walking) measures of health-related quality of life to generic preference-based measures to generate utility values. Applied Health Economics and Health Policy, 17, 295–313.PubMed
45.
Wilhelm, M. O. (2008). Practitioners’ corner: Practical considerations for choosing between tobit and scls or clad estimators for censored regression models with an applicationto charitable giving. Oxford Bulletin of Economics and Statistics, 70, 559–582.
46.
Powell, J. L. (1984). Least absolute deviations estimation for the censored regression model. Journal of Econometrics, 25, 303–325.
47.
Hernández Alava, M., Wailoo, A. J., & Ara, R. (2012). Tails from the peak district: Adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value in Health, 15, 550–561.PubMed
48.
Hernández Alava, M., & Wailoo, A. (2015). Fitting adjusted limited dependent variable mixture models to EQ-5D. Stata Journal, 15, 737–750.
49.
Gillard, P. J., Devine, B., Varon, S. F., Liu, L., & Sullivan, S. D. (2012). Mapping from disease-specific measures to health-state utility values in individuals with migraine. Value in Health, 15, 485–494.PubMed
50.
Paduano, D., Cingolani, A., Tanda, E., & Usai, P. (2019). Effect of three diets (low-FODMAP, gluten-free and balanced) on irritable bowel syndrome symptoms and health-related quality of life. Nutrients., 11, 1566.PubMedCentral
51.
Cañón, M., Ruiz, A. J., Rondón, M., & Alvarado, J. (2017). Prevalence of irritable bowel syndrome and health-related quality of life in adults aged 18 to 30 years in a Colombian university: An electronic survey. Annals of Gastroenterology, 30, 67–75.PubMed
52.
Kim, Y. S., Choi, S. C., Park, J. M., Choi, C. H., Lee, D. H., Son, H. J., et al. (2010). The effect of Tegaserod on symptoms and quality of life in Korean women with irritable bowel syndrome with constipation. Journal of Neurogastroenterology and Motility, 16, 61–70.PubMedPubMedCentral
53.
Kopczynska, M., Mokros, L., Pietras, T., & Malecka-Panas, E. (2018). Quality of life and depression in patients with irritable bowel syndrome. Przeglad Gastroenterologiczny, 13, 102–108.PubMedPubMedCentral
54.
Mulhern, B., Pink, J., Rowen, D., Borghs, S., Butt, T., Hughes, D., et al. (2017). Comparing generic and condition-specific preference-based measures in epilepsy: EQ-5D-3L and NEWQOL-6D. Value in Health, 20, 687–693.PubMed
55.
Lorgelly, P. K., Doble, B., Rowen, D., Brazier, J., Thomas, D. M., Fox, S. B., et al. (2017). Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. Quality of Life Research, 26, 1163–1176.PubMed
56.
57.
Haywood, K. L., Garratt, A. M., Lall, R., Smith, J. F., & Lamb, S. E. (2008). EuroQol EQ-5D and condition-specific measures of health outcome in women with urinary incontinence: Reliability, validity and responsiveness. Quality of Life Research, 17, 475–483.PubMed
58.
59.
Midenfjord, I., Borg, A., Törnblom, H., & Simrén, M. (2021). Cumulative effect of psychological alterations on gastrointestinal symptom severity in irritable bowel syndrome. The American Journal of Gastroenterology, 116, 769–779.PubMed
60.
Portincasa, P., Bonfrate, L., Scribano, M. L., Kohn, A., Caporaso, N., Festi, D., et al. (2016). Curcumin and fennel essential oil improve symptoms and quality of life in patients with irritable bowel syndrome. Journal of Gastrointestinal and Liver Diseases, 25, 151–157.PubMed
61.
Everitt, H. A., Landau, S., O’Reilly, G., Sibelli, A., Hughes, S., Windgassen, S., et al. (2019). Cognitive behavioural therapy for irritable bowel syndrome: 24-Month follow-up of participants in the ACTIB randomised trial. The Lancet Gastroenterology and Hepatology, 4, 863–872.PubMed
62.
Fayers, P. M., & Hays, R. D. (2014). Should linking replace regression when mapping from profile-based measures to preference-based measures? Value in Health, 17, 261–265.PubMedPubMedCentral
63.
van Hout, B., Janssen, M. F., Feng, Y. S., Kohlmann, T., Busschbach, J., Golicki, D., et al. (2012). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health, 15, 708–715.PubMed
Metadata
Title
The estimation of a preference-based single index for the IBS-QoL by mapping to the EQ-5D-5L in patients with irritable bowel syndrome
Authors
Rosel Sturkenboom
Daniel Keszthelyi
Lloyd Brandts
Zsa Zsa R. M. Weerts
Johanna T. W. Snijkers
Ad A. M. Masclee
Brigitte A. B. Essers
Publication date
01-04-2022
Publisher
Springer International Publishing
Published in
Quality of Life Research / Issue 4/2022
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-021-02995-y

Other articles of this Issue 4/2022

Quality of Life Research 4/2022 Go to the issue

Correction

Correction to: Efficacy of physical therapy interventions on quality of life and upper quadrant pain severity in women with post-mastectomy pain syndrome: a systematic review and meta-analysis

OriginalPaper

Measurement invariance of the Seattle Angina Questionnaire in coronary artery disease

Commentary

Transforming challenges into opportunities: conducting health preference research during the COVID-19 pandemic and beyond

OriginalPaper

BMI and dissatisfaction with life: contextual factors and socioemotional costs of obesity

OriginalPaper

Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2

OriginalPaper

A longitudinal view of successful aging with HIV: role of resilience and environmental factors